Clinical trials: Dementia Disorders
Alzheimer's Disease
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812…
- Trial name
- NCT02907567
- Testing
- CT1812
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease, Healthy
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.
- Trial name
- NCT00901498
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Alzheimer's Disease, Dementia
LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia
The LifeZig Project is a research study of a new reminiscence activity for individuals with Alzheimer's Disease (AD) and other types of dementia, based on the LifeZig system, with personalized video channels containing old…
- Trial name
- Lifezig (NCT00759863)
- Testing
- Lifezig
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Photozig, Inc.
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio
Alzheimer's Disease
A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.
- Trial name
- NCT00459550
- Testing
- GSK933776
- Where
- 7 sites in Australia, Norway and 1 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Agitation in Dementia
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
This study tests a medication called dronabinol in people with Alzheimer's disease. First, participants go through up to 4 weeks of screening. Then, over 2 weeks, the dose of the study drug is slowly increased.
- Trial name
- NCT07422311
- Testing
- Dronabinol Oral Solution
- Where
- Australia
- Volunteers
- 140 people
- Sponsor
- Benuvia Therapeutics Inc.
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).
- Trial name
- NCT00285077
- Testing
- SR57667B
- Where
- 7 sites in Canada, Denmark and 5 more
- Volunteers
- 390 people
- Sponsor
- Sanofi
Alzheimer's Disease
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.
- Trial name
- AID (NCT02158910)
- Testing
- Aricept
- Where
- 13 sites in South Korea
- Volunteers
- 2,231 people
- Sponsor
- Eisai Korea Inc.
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
- Trial name
- NCT05665088
- Testing
- BXCL501
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- BioXcel Therapeutics Inc
Cadasil
CERebrolysin In CADASIL
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL.
- Trial name
- CERICA (NCT05755997)
- Testing
- Cerebrolysin, 0.9 % NaCl
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Early Onset
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
- Trial name
- TargetTau-1 (NCT06268886)
- Testing
- BMS-986446
- Where
- 176 sites in United States, Australia and 8 more
- Volunteers
- 310 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
The objective of this trial was to assess the dose-response relationship of symptomatic efficacy of talsaclidine base on ADAScog and to assess safety and tolerability
- Trial name
- NCT02249403
- Testing
- Talsaclidine 6 mg, Talsaclidine 12 mg, Talsaclidine 24 mg
- Volunteers
- 362 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease.
- Trial name
- REVERSE-SD (NCT03402659)
- Testing
- neflamapimod
- Where
- 38 sites in United States, Czechia and 3 more
- Volunteers
- 161 people
- Sponsor
- EIP Pharma Inc
Alzheimer Disease
Tricaprilin Liquid Formulation PK Study
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to advance in development.
- Trial name
- NCT05028114
- Testing
- AC-1202, AC-OLE-01, AC-OLE-02
- Where
- Australia
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT01249196
- Testing
- SK-PC-B70M
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- SK Chemicals Co., Ltd.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.